Analyst Puneet Souda from Leerink Partners maintained a Buy rating on Natera and increased the price target to $235.00 from $220.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Puneet Souda has given his Buy rating due to a combination of factors that highlight Natera’s strong growth potential and strategic positioning in the market. The company is leading in the minimal residual disease (MRD) sector, which is significantly underpenetrated, presenting a substantial opportunity in a $20 billion market. Natera’s recent performance, particularly with its Signatera tests, has exceeded expectations, with a notable increase in clinical tests and revenue growth projections.
Natera’s management has maintained operational expenditure guidance while expanding into new markets and initiatives, such as AI and organ health, which provides confidence in their strategic direction. The company’s ability to consistently outperform expectations, coupled with upcoming catalysts like potential guideline inclusions and advancements in their product offerings, supports the optimistic outlook. These factors, along with a raised price target, underscore the Buy rating as Natera continues to demonstrate robust growth and market leadership.
In another report released on August 9, TR | OpenAI – 4o also upgraded the stock to a Buy with a $167.00 price target.
NTRA’s price has also changed slightly for the past six months – from $169.710 to $157.040, which is a -7.47% drop .